Bristol Myers Squibb Gains FDA Priority Review for Opdivo in Hodgkin Lymphoma
Key Insights
The FDA granted Priority Review for Bristol Myers Squibb (search)'s supplemental Biologics License Application for Opdivo combined with AVD chemotherapy in advanced classical Hodgkin lymphoma (search), setting an action date of April 8, 2026.
The company secured an expanded label for CAR-T therapy Breyanzi for marginal zone lymphoma (search) treatment on December 5, 2025, broadening its addressable patient population.
Promising Phase 2 data for bispecific antibody candidate pumitamig (search) in advanced triple-negative breast cancer (search) were presented, strengthening the company's growth portfolio.
Bristol Myers Squibb (search) received a significant regulatory boost as the FDA granted Priority Review for its supplemental Biologics License Application for Opdivo (nivolumab) in combination with AVD chemotherapy for advanced classical Hodgkin lymphoma (search). The designation sets a Prescription Drug User Fee Act target action date of April 8, 2026, accelerating the standard review timeline.
The application seeks approval for Opdivo combined with AVD chemotherapy (doxorubicin, vinblastine, dacarbazine) for first-line treatment of advanced classical Hodgkin lymphoma (search) in adults and adolescents aged 12 and older. The submission is supported by positive results from the Phase 3 SWOG S1826 study, and a successful approval would mark a major new indication for this cornerstone oncology drug.
Expanding CAR-T Portfolio
Bristol Myers Squibb (search) also secured an expanded label for its CAR-T cell therapy Breyanzi (lisocabtagene maraleucel) for the treatment of marginal zone lymphoma (search) on December 5, 2025. This regulatory approval broadens the addressable patient population for this advanced therapy, strengthening the company's position in the cell therapy market.
Promising Pipeline Data
The company presented encouraging Phase 2 data for bispecific antibody candidate pumitamig (search) (BNT327/BMS986545 (search)), developed in collaboration with BioNTech, on December 9, 2025. The data in advanced triple-negative breast cancer (search) underscore the potential of this partnered asset and highlight the company's diversified approach to oncology drug development.
Market Response and Analyst Views
Bristol Myers Squibb (search) stock gained 2.54% following these regulatory advances, with shares closing at €44.77 on Friday. Despite a year-to-date decline of approximately 19%, recent developments have generated positive momentum.
Guggenheim (search) upgraded its rating on Bristol Myers Squibb (search) shares to "Buy" on December 12, contrasting with mixed analyst sentiment. Morgan Stanley (search) maintained an "Underweight" rating while slightly raising its price target, and William Blair (search) confirmed a "Hold" position. Wells Fargo (search) kept an "Equal-Weight" rating while also increasing its target. The consensus rating among 11 analysts as of December 13 remained at "Hold."
Financial Performance
The company demonstrated strong operational metrics with a 20.8% EBIT margin and robust gross margin of 69.5%. Revenue reached nearly $48.3 billion with an exceptionally healthy cash position, showcasing substantial liquidity and operational efficiency. The pretax profit margin of 5.7% reflects solid earning strategy compared to industry standards, while the PE ratio of 17.65 suggests reasonable valuation territory.
Bristol Myers Squibb (search) also announced a 1.6% increase in its quarterly dividend to $0.63 per share, marking the 17th consecutive year of dividend growth and demonstrating commitment to shareholder value.
Strategic Outlook
These regulatory milestones represent crucial elements in Bristol Myers Squibb (search)'s strategy to diversify future revenue streams as the company navigates patent cliff pressures. The April 8, 2026 PDUFA date for Opdivo's Hodgkin lymphoma application will serve as a pivotal catalyst, with regulatory decisions and additional clinical trial readouts expected to drive stock performance in the coming months.